{"entity":{"id":"nct07791758","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","aka":[],"tldr":"A phase 1/2 trial of bevacizumab, oxaliplatin and capecitabine in colorectal cancer, run by Nanjing Leads Biolabs Co.,Ltd, not yet recruiting.","summary":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma is a phase 1/2, randomised interventional study registered as NCT07791758 by Nanjing Leads Biolabs Co.,Ltd, with a registry enrolment figure of 369 participants, started 2026-09-04 and due to reach its primary completion in 2030-09-04. Interventions recorded: LBL-024 for Injection; Bevacizumab injection; Oxaliplatin injection; Capecitabine tablets; Fruquintinib Capsules. Conditions listed: Metastatic Colorectal Carcinoma. Primary outcome: Objective Response Rate (ORR); Occurrence of adverse event (AE) and serious adverse event (SAE). Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07791758","url":"https://clinicaltrials.gov/study/NCT07791758"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","monoclonal-antibody","platinum"],"targets":[],"drugs":["bevacizumab","oxaliplatin","capecitabine"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07791758","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":369,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07791758/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}